Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma

Carcinogenesis

Volumn 30, Issue 7, 2009, Pages 1139-1146

  Komatsu, Shuhei ^a,b   Imoto, Issei ^a   Tsuda, Hitoshi ^a,c   Kozaki, Ken Ich ^a   Muramatsu, Tomoki ^a   Shimada, Yutaka ^d   Aiko, Satoshi ^c   Yoshizumi, Yutaka ^c   Ichikawa, Daisuke ^b   Otsuji, Eigo ^b   Inazawa, Johji ^a,b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^d UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; METHYLTRANSFERASE; ONCOPROTEIN; PROTEIN P53; SET AND MYND DOMAIN CONTAINING PROTEIN 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL; CANCER STAGING; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENDER; GENE ACTIVATION; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; SURVIVAL RATE; TRANSACTIVATION; TRANSCRIPTION REGULATION;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; FEMALE; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67650102336     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp116     Document Type: Article

References (31)

1. Kamangar,F. et al. (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol., 24, 2137-2150.
2. Lam,A.K. (2000) Molecular biology of esophageal squamous cell carcinoma. Crit. Rev. Oncol. Hematol., 33, 71-90.
3. Pimkhaokham,A. et al. (2000) Nonrandom chromosomal imbalances in esophageal squamous cell carcinoma cell lines: Possible involvement of the ATF3 and CENPF genes in the 1q32 amplicon. Jpn. J. Cancer Res. 91, 1126-1133.
4. Inazawa,J. et al. (2004) Comparative genomic hybridization (CGH)-arrays pave the way for identification of novel cancer-related genes. Cancer Sci., 95, 559-563.
5. Sonoda,I. et al. (2004) Frequent silencing of low density lipoprotein receptor-related protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in esophageal squamous cell carcinoma. Cancer Res., 64, 3741-3747.
6. Rooney,P.H. et al. (1999) Comparative genomic hybridization and chromosomal instability in solid tumours. Br. J. Cancer, 80, 862-873.
7. Gaudray,P. et al. (1992) DNA amplification at 11q13 in human cancer: From complexity to perplexity. Mutat. Res., 276, 317-328.
8. Khatib,Z.A. et al. (1993) Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res., 53, 5535-5541.
9. Brown,M.A. et al. (2006) Identification and characterization of Smyd2: A split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex. Mol. Cancer, 5, 26.
10. Huang,J. et al. (2006) Repression of p53 activity by Smyd2-mediated methylation. Nature, 444, 629-632.
11. Caelles,C. et al. (1994) p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature, 370, 220-223.
12. Sarbia,M. et al. (1998) Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities. Clin. Cancer Res., 4, 2991-2997.
13. Natsugoe,S. et al. (1999) Expression of p21WAF1/Cip1 in the p53-dependent pathway is related to prognosis in patients with advanced esophageal carcinoma. Clin. Cancer Res., 5, 2445-2449.
14. Shimada,Y. et al. (1992) Characterization of 21 newly established esophageal cancer cell lines. Cancer, 69, 277-284.
15. 2/M arrest. Oncogene, 26, 1110-1121.
16. Sobin,L.H. et al. (eds) (2002) International Union Against Cancer (UICC): TNM Classification of Malignant Tumors. 6th edn. Wiley-Less, New York, NY.
17. Yu,W. et al. (2007) A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity. Oncogene, 26, 1178-1187.
18. Naoi,Y. et al. (2008) Connexin26 expression is associated with aggressive phenotype in human papillary and follicular thyroid cancers. Cancer Lett., 262, 248-256.
19. Bennett,W.P. et al. (1991) Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer. Oncogene, 6 1779-1784.
20. Wagata,T. et al. (1993) Loss of 17p, mutation of p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Cancer Res., 53, 846-850.
21. Sarbia,M. et al. (1994) p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer, 74, 2218-2223.
22. Kanamoto,A. et al. (1999) No prognostic significance of p53 expression in esophageal squamous cell carcinoma. J. Surg. Oncol., 72, 94-98.
23. Wang,D.Y. et al. (1994) High prevalence of p53 protein overexpression in patients with esophageal cancer in Linxian, China and its relationship to progression and prognosis. Cancer, 74, 3089-3096.
24. Okumura,H. et al. (2006) Expression of p53R2 is related to prognosis in patients with esophageal squamous cell carcinoma. Clin. Cancer Res., 12, 3740-3745.
25. Weinstein,I.B. (2002) Cancer: Addiction to oncogenes - the Achilles heal of cancer. Science, 297, 63-64.
26. Weinstein,I.B. et al. (2006) Mechanisms of disease: Oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol., 3, 448-457.
27. Bannister,A.J. et al. (2005) Spatial distribution of di- and tri-methyl lysine 36 of histone H3 at active genes. J. Biol. Chem. 280, 17732-17736.
28. Abu-Farha,M. et al. (2008) The tale of two domains: Proteomics and genomics analysis of SMYD2, a new histone methyltransferase. Mol. Cell. Proteomics, 7, 560-572.
29. Hamamoto,R. et al. (2004) SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat. Cell Biol., 6, 731-740.
30. Tsuge,M. et al. (2005) Avariable number of tandem repeats polymorphism in an E2F-1 binding element in the 5′ flanking region of SMYD3 is a risk factor for human cancers. Nat. Genet., 37, 1104-1107.
31. Kunizaki,M. et al. (2007) The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3. Cancer Res., 67, 10759-10765.